X-Linked Retinitis Pigmentosa Market: Accelerating Growth and Pipeline Impact by 2034 - DelveInsight

The X-Linked Retinitis Pigmentosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage X-Linked Retinitis Pigmentosa pipeline products will significantly revolutionize the X-Linked Retinitis Pigmentosa market dynamics.

DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the X-Linked Retinitis Pigmentosa, historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The X-Linked Retinitis Pigmentosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the X-Linked Retinitis Pigmentosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; X-Linked Retin itis Pigmentosa Market Forecast
https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the X-Linked Retinitis Pigmentosa Market Report:
• The X-Linked Retinitis Pigmentosa market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In September 2025, Beacon Therapeutics announced topline results from two Phase 2 studies SKYLINE and DAWN evaluating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP). The findings were presented at the 2025 European Society of Retina Specialists (EURETINA) Annual Meeting, held from September 4-7 in Paris.
• In January 2025, The U.S. Food and Drug Administration (FDA) has awarded Regenerative Medicine Advanced Therapy (RMAT) designation to laruparetigene zovaparvovec (laru-zova), developed by Beacon Therapeutics Holdings Ltd, for the treatment of X-linked retinitis pigmentosa (XLRP). The RMAT program is designed to accelerate the development and regulatory review of regenerative therapies that address serious or life-threatening conditions with significant unmet medical needs. Commenting on the milestone, Beacon Therapeutics CEO Dr. Lance Baldo stated that the designation represents an important advancement for the XLRP community and highlights the encouraging clinical data and the potential of laru-zova to meaningfully improve patient outcomes. He added that the company looks forward to continued collaboration with the FDA to advance laru-zova through an accelerated development and review pathway.
• The US market size for retinitis pigmentosa was approximately USD 270 million in 2023 and is anticipated to grow with the introduction of new emerging therapies.
• In June 2024, Beacon Therapeutics has initiated its registrational VISTA clinical trial by treating the first patient with its leading candidate, AGTC-501. The company intends to utilize data from the VISTA trial, along with findings from the Phase I/II HORIZON and Phase II SKYLINE studies, including comprehensive long-term data, to support a BLA submission in the US and an MAA submission in Europe for the treatment of XLRP patients.
• In its Q2 2024 financial report and operational highlights, 4D Molecular Therapeutics announced that updates on the 4D-125 program for XLRP are anticipated in Q4 2024.
• In February 2024, Beacon Therapeutics revealed the 12-month interim safety and efficacy results for the Phase II SKYLINE trial in XLRP patients at the 47th Annual Macula Society Meeting. AGTC-501 was well tolerated, with no clinically significant safety concerns. Treatment-related adverse events were generally mild to moderate and nonserious.
• In March, MeiraGTx received a USD 50 million milestone payment following the initiation of the extension study for the Phase III LUMEOS clinical trial of bota-vec for treating XLRP.
• According to DelveInsight's estimates, there were approximately 274,100 prevalent cases of retinitis pigmentosa in the 7MM in 2023, with numbers projected to increase over the forecast period.
• In 2023, there were approximately 113,200 prevalent cases of retinitis pigmentosa in the US, with XLRP accounting for around 11,000 of these cases.
• Non-syndromic retinitis pigmentosa is more common than its syndromic counterpart, representing approximately 65% of all retinitis pigmentosa cases.
• Non-syndromic retinitis pigmentosa constitutes about 65% of all retinitis pigmentosa cases. Among these, autosomal recessive forms make up approximately 10-15%, autosomal dominant forms account for 20-25%, and XLRP is the rarest type, characterized by early onset and severe vision loss.
• DelveInsight reports that XLRP represented approximately 15% of non-syndromic retinitis pigmentosa cases in the 7MM, with around 16,500 cases recorded in 2023.
• Emerging companies like MeiraGTx/Johnson & Johnson Innovative Medicine, Beacon Therapeutics, 4D Molecular Therapeutics, and others are actively developing therapies for XLRP. Frontera Therapeutics' FT-002, a gene therapy targeting RPGR gene mutation-related XLRP, is currently in the early stages of clinical development.
• Key X-Linked Retinitis Pigmentosa Companies: Beacon Therapeutics, 4D Molecular Therapeutics, SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Coave Therapeutics, jCyte, Nightstar Therapeutics, ReNeuron, and others
• Key X-Linked Retinitis Pigmentosa Therapies: AGTC-501, 4D-125, CTx-PDE6b, jCell, AAV8-RPGR, BIIB112, Human retinal progenitor cells (hrpc) cell, and others
• The X-Linked Retinitis Pigmentosa epidemiology based on gender analyzed that a higher percentage of diagnosed prevalence was observed for males, in comparison to females, except Japan, where females occupy a larger patient pool than males

X-Linked Retinitis Pigmentosa Overview
X-Linked Retinitis Pigmentosa (XLRP) is a rare genetic disorder affecting the retina, the light-sensitive tissue at the back of the eye. It is an inherited form of retinitis pigmentosa (RP) caused by mutations in genes located on the X chromosome, predominantly affecting males. XLRP leads to the progressive degeneration of photoreceptor cells, causing symptoms such as night blindness, loss of peripheral vision, and eventually central vision impairment. Onset typically occurs in childhood or adolescence, with vision gradually worsening over time. There is no cure yet, but ongoing research focuses on gene therapies and other treatments to slow disease progression.

Get a Free sample for the X-Linked Retinitis Pigmentosa Market Report:
https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

X-Linked Retinitis Pigmentosa Market
The dynamics of the X-Linked Retinitis Pigmentosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
X-Linked Retinitis Pigmentosa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

X-Linked Retinitis Pigmentosa Epidemiology Segmentation:
The X-Linked Retinitis Pigmentosa market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of X-Linked Retinitis Pigmentosa
• Prevalent Cases of X-Linked Retinitis Pigmentosa by severity
• Gender-specific Prevalence of X-Linked Retinitis Pigmentosa
• Diagnosed Cases of Episodic and Chronic X-Linked Retinitis Pigmentosa

Download the report to understand which factors are driving X-Linked Retinitis Pigmentosa epidemiology trends @ X-Linked Retinitis Pigmentosa Epidemiological Insights
https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

X-Linked Retinitis Pigmentosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the X-Linked Retinitis Pigmentosa market or expected to get launched during the study period. The analysis covers X-Linked Retinitis Pigmentosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the X-Linked Retinitis Pigmentosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

X-Linked Retinitis Pigmentosa Therapies and Key Companies
• AGTC-501: Beacon Therapeutics
• 4D-125: 4D Molecular Therapeutics
• EA-2353: Endogena Therapeutics, Inc
• OCU400-301: Ocugen
• BS01: Bionic Sight LLC
• CPK850: Novartis
• AAV2/5-hPDE6B: eyeDNA Therapeutics
• hRPC: ReNeuron Limited
• SPVN06: SparingVision
• RST-001: AbbVie
• KIO-301: Kiora Pharmaceuticals
• OCU400: Ocugen
• QR-1123: ProQR Therapeutics
• Ultevursen: ProQR Therapeutics

To know more about X-Linked Retinitis Pigmentosa treatment, visit @ X-Linked Retinitis Pigmentosa Medications
https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

X-Linked Retinitis Pigmentosa Market Strengths
• AAVs have emerged as the predominant vectors for delivering genes of interest to target tissues with improved specificity, efficiency, and safety in the case of X-Linked Retinitis Pigmentosa.
• Gene therapy is advancing by leaps and bounds as it is more effective, less invasive, and relatively safer in the short term than retinal transplantation.

X-Linked Retinitis Pigmentosa Market Opportunities
• Alongside advances in cell and gene technologies, research advances in the fields of optogenetics and electronic retinal prostheses also represent encouraging progress for the treatment of X-Linked Retinitis Pigmentosa and other inherited retinal dystrophies.
• Cell therapies such as jCell by jCyte, once approved, will likely have a broad application as they are mutation-independent. Treatment can be initiated earlier as cell therapies do not require genetic testing.

Scope of the X-Linked Retinitis Pigmentosa Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key X-Linked Retinitis Pigmentosa Companies: Beacon Therapeutics, 4D Molecular Therapeutics, SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, Coave Therapeutics, jCyte, Nightstar Therapeutics, ReNeuron, and others
• Key X-Linked Retinitis Pigmentosa Therapies: AGTC-501, 4D-125, CTx-PDE6b, jCell, AAV8-RPGR, BIIB112, Human retinal progenitor cells (hrpc) cell, and others
• X-Linked Retinitis Pigmentosa Therapeutic Assessment: X-Linked Retinitis Pigmentosa current marketed and X-Linked Retinitis Pigmentosa emerging therapies
• X-Linked Retinitis Pigmentosa Market Dynamics: X-Linked Retinitis Pigmentosa market drivers and X-Linked Retinitis Pigmentosa market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• X-Linked Retinitis Pigmentosa Unmet Needs, KOL's views, Analyst's views, X-Linked Retinitis Pigmentosa Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.